#China #VivaVision #Wenzhou #ophthalmology #Quan Dong Nguyen

VivaVision Biotech Enhances Advisory Board with World-Class Osteopath

VivaVision Biotech (Zhejiang) Co., Ltd, a promising name in the pharmaceutical sector dedicated to innovative ocular therapies, has made headlines yet again. The company recently appointed Dr. Quan Dong Nguyen, a distinguished ophthalmologist, to its Scientific Advisory Board (SAB). This strategic decision aims to leverage Dr. Nguyen's extensive knowledge and experience in the field of eye care to bolster VivaVision's ongoing commitment to pioneering treatments for ocular diseases.

A Closer Look at Dr. Quan Dong Nguyen's Credentials

Dr. Quan Dong Nguyen is a professor of ophthalmology at Stanford University's Byers Eye Institute and boasts an impressive educational background. He earned his B.S. and M.Sc. in Molecular Biophysics and Biochemistry from Yale, followed by an M.D. from the University of Pennsylvania. His professional journey includes comprehensive training, including an internal medicine internship at Massachusetts General Hospital and an ophthalmology residency at Harvard Medical School's Massachusetts Eye and Ear Infirmary.

With a wealth of experience, Dr. Nguyen is currently a principal investigator for various clinical trials focused on critical conditions like macular edema due to diabetes and uveitis, as well as neovascular age-related macular degeneration (AMD). His involvement in pioneering studies has been pivotal, as he was among the first scientists to test the safety and efficacy of significant drugs such as aflibercept and ranibizumab, which now form the foundation of anti-VEGF therapies for retinal vascular diseases.

Notably, Dr. Nguyen has also led several major clinical trials, including the READ-2, READ-3, ACTHAR, and ATLAS studies. His affiliation with prestigious organizations like the Retina Society and the American Uveitis Society speaks to his influence and contribution to the field, having been elected as President of the International Ocular Inflammation Society.

What This Means for VivaVision Biotech

According to Dr. Wang Shen, the Founder and CEO of VivaVision, the addition of Dr. Nguyen to the SAB represents a monumental step toward advancing the company’s innovative pipeline. He expressed enthusiasm about collaborating with Dr. Nguyen, particularly regarding their dual JAK1/TYK2 inhibitors, VVN461 and VVN481 – both of which are poised to offer groundbreaking treatment for patients suffering from ocular inflammatory diseases.

Professor Nguyen has emphasized the potential of VivaVision's JAK1/TYK2 inhibitor to serve as a vital therapeutic option for patients reliant on corticosteroids for managing ocular conditions. His insights will be invaluable in guiding the company’s clinical programs and trials, further enhancing their development of promising therapeutic candidates.

VivaVision's Innovative Pipeline

Founded in 2016, VivaVision Biotech aims to develop first-in-class and best-in-class therapies for ocular ailments. Their current pipeline includes:
1. VVN461: A non-steroidal dual JAK1/TYK2 immunomodulator intended for post-operative inflammation post-cataract surgery.
2. VVN001: A potential treatment for dry eye disease.
3. VVN1901: Targeting neurotrophic keratitis.
4. VVN481: A non-steroidal dual JAK1/TYK2 inhibitor for suprachoroidal injection, aimed at treating posterior and pan-uveitis.

VivaVision is not just focused on its existing pipeline but is also actively pursuing the development of innovative therapies to address the unmet needs in ocular health.

Conclusion

The appointment of Dr. Quan Dong Nguyen is a noteworthy enhancement to VivaVision Biotech’s advisory capabilities, setting a promising stage for significant advancements in the field of ophthalmology. As the company seeks to climb the ranks in ocular drug discovery globally, the invaluable expertise of Dr. Nguyen is expected to provide crucial guidance in fulfilling their mission. For more information about their innovative approach to ocular therapies, visit VivaVision Biotech.